EDAP TMS SA secured a €36 million credit facility from the European Investment Bank to expand Focal One Robotic HIFU technology for early-stage prostate cancer treatment. The low-interest funding, accessible in tranches, will strengthen EDAP's balance sheet and accelerate the development of new clinical indications. CEO Ryan Rhodes expressed confidence that this financial support will enhance growth initiatives and expand access to their innovative technology.
EDAP TMS SA (NASDAQ: EDAP), a leader in robotic energy-based therapies, has secured a €36 million credit facility from the European Investment Bank (EIB). The financing, expected to close by the end of 2025, will support the continued expansion of Focal One Robotic HIFU in Focal Therapy, a treatment category for early-stage prostate cancer, and accelerate the development of new clinical indications [1][2].
The low-interest funding, accessible in tranches, will strengthen EDAP's balance sheet and provide a substantial source of capital to support its growth initiatives. CEO Ryan Rhodes expressed confidence that this financial support will enhance growth initiatives and expand access to their innovative technology [2].
EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices using ultrasound technology. The Focal One® technology is the leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer [2].
This strategic financing aligns with EDAP's mission to deliver innovative technologies for the benefit of millions of patients across the globe. The EIB has been a key partner in supporting such initiatives, providing low-interest funding that can be accessed in tranches as needed [1][2].
References:
[1] https://seekingalpha.com/news/4489116-edap-executes-letter-of-intent-for-36m-financing-from-european-investment-bank
[2] https://www.stocktitan.net/news/EDAP/edap-announces-letter-of-intent-for-36-million-euro-credit-facility-2ymdylq9plat.html
Comments
No comments yet